【Nihon Shinyaku】2026 Fiscal Year Financial Results｜Sales of ¥170.7 billion (YoY +6.6%)

Performance Overview

For the fiscal year ending March 2026, consolidated sales amounted to ¥170.71 billion, an increase of 6.6% YoY, primarily driven by expanded sales of new pharmaceuticals and increased overseas royalty income. Operating income was approximately ¥35.49 billion, remaining almost flat, while net income attributable to shareholders declined by 8.7% to ¥29.72 billion due to increased corporate taxes. Segments-wise, both the pharmaceuticals and functional foods businesses saw revenue growth. The company continues to expect growth through new drug launches and overseas expansion. R&D efforts are also active, with numerous clinical trials underway.

Outlook and Shareholder Returns

Forecasts for the fiscal year ending March 2027 project consolidated sales of ¥200.00 billion, operating income of ¥38.00 billion, and net income attributable to owners of the parent of ¥30.30 billion. The company plans to maintain an annual dividend of ¥124 per share, ensuring stable shareholder returns. It aims to accelerate new drug development and overseas expansion while balancing research investment and profit sharing to achieve sustainable growth.